A Clinical Trial to Evaluate the Pharmacokinetics and Safety of SIPS-2209-1 in Healthy Korean Volunteers
NCT ID: NCT05787873
Last Updated: 2023-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2022-08-30
2022-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State
NCT05739851
Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State
NCT05739877
Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State
NCT05739916
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers
NCT05548387
A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402
NCT02897726
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
Period 1: SIPS-2209-1 - A single oral dose of 1 tablet under fasting condition
Period 2: SIPS-2209-2, SIPS-2209-3 - A single oral dose of 2 tablets under fasting condition
SIPS-2209-1
QD, PO
SIPS-2209-2, SIPS-2209-3
QD, PO
Sequence B
Period 1: SIPS-2209-2, SIPS-2209-3 - A single oral dose of 2 tablets under fasting condition
Period 2: SIPS-2209-1 - A single oral dose of 1 tablet under fasting condition
SIPS-2209-1
QD, PO
SIPS-2209-2, SIPS-2209-3
QD, PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SIPS-2209-1
QD, PO
SIPS-2209-2, SIPS-2209-3
QD, PO
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male for body weight ≥50 kg, female for body weight ≥45 kg
3. Calculated body mass index (BMI) of 18 to 30 kg/m2
4. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.
5. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and ECG results at screening.
6. Those who agree to contraception during the participation of clinical trial.
7. Those who agrees to exclude the possibility of pregnancy by using a medically accepted method of contraception from the first administration of investigational medicine to 7 days after the last administration of investigational medicine
Exclusion Criteria
2. Those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month and those who take drug could affect to clinical trial within 10 days before the first administration of investigational products.
3. Those who donated whole blood or apheresis within 8 weeks or 2 weeks respectfully, or received blood transfusion within a month.
4. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.
5. Those who exceed an alcohol and cigarette consumption criteria write below within 1 month before the first administration of investigational products.
* Alcohol: Man - 21 glasses/week, Woman - 14 glasses/week (1 glass: Soju 50mL, Wine 30mL, or beer 250mL)
6. Patients with the following diseases
* Patients with known hypersensitivity reactions such as anaphylaxis or angioedema to investigational drugs and components
* Patients with pancreatitis
* Patients with heart failure or a history of heart failure
* Patients with active bladder cancer or a history of bladder cancer
* Patients with hepatic impairment
* Patients with severe renal impairment
* Patients with diabetic ketoacidosis, diabetic coma and pre-coma, patients with type 1 diabetes
* Before and after surgery, patients with severe infections, patients with severe trauma
* Patients with gross hematuria not investigated
* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
7. Those who are deemed insufficient to participate in this clinical trial by investigators.
8. Woman who are pregnant or breastfeeding.
9. Those who have a history of clinically significant mental illness
19 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samik Pharmaceutical Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young Ee KWON, Ph.D
Role: STUDY_DIRECTOR
Samik Pharmaceutical Co. Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samik Pharmaceutical Co. Ltd.
Incheon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIPS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.